Iclusig (ponatinib hydrochloride)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) June 2016 WARNINGS AND PRECAUTIONS Increased Toxicity in Newly Diagnosed Chronic Phase CML In a prospective randomized clinical...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts